SecBot SecBot
PRESS-RELEASE ·Filed Jun 1, 2026

RMD

Resmed, Inc.
BULLISH
Impact 5/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▲ Bullish

Monitor Resmed's upcoming quarterly reports for any contribution from Noctrix's Nidra therapy and management commentary on RLS market penetration. The acquisition strengthens Resmed's sleep health offering beyond sleep apnea, but financial impact is likely modest in the near term.

DirectionBullish
Confidencemedium
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$182.75
T+0 close · Jun 1, 2026 · via day close
Latest settled
+28.97%
T+60 · $235.69
Vs SPY
+28.11%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 2 $182.75entry
  2. T+1 · 6mo ago +1.71%α +2.43% · $185.87
  3. T+5 · 5mo ago +7.77%α +10.73% · $196.94
  4. T+20 · 5mo ago +10.04%α +11.86% · $201.10
  5. T+60 · 3mo ago +28.97%α +28.11% · $235.69

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Resmed completed its acquisition of Noctrix Health, adding an FDA-cleared non-pharmacologic treatment for Restless Legs Syndrome (RLS) to its sleep health portfolio. The deal size was not disclosed, but the acquisition aligns with Resmed's 2030 strategy and expands its clinical sleep health offering beyond sleep apnea into RLS, the third most prevalent sleep disorder.

Key Facts

  • Resmed completed acquisition of Noctrix Health on June 1, 2026.
  • Noctrix's Nidra TOMAC Therapy is an FDA De Novo classified non-invasive treatment for moderate-to-severe RLS.
  • The therapy is included in AASM clinical practice guidelines and supported by 10 peer-reviewed publications.
  • Noctrix becomes a wholly owned subsidiary of Resmed.
  • Financial terms of the acquisition were not disclosed.

Financial Impact

Not disclosed; strategic acquisition expected to expand portfolio into adjacent RLS market.

revenueportfolio diversification

Risk Factors

  • Integration and commercial execution of Noctrix's therapy into Resmed's portfolio.
  • RLS treatment market adoption and reimbursement uncertainties.
  • Potential for lower-than-expected revenue contribution from the newly acquired asset.

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
62% bullish (26 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3304704

Track record

19 reports on RMD

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +10.92% at T+20 after the May 19, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 9, 20267d ago 144 Neutral 2/10 Entry $234.11 Now $238.19 +1.74% settles Dec 9
  2. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  3. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $229.94 Now $238.19 +3.59% settles Nov 30
  4. Oct 16, 20264w ago Institutional Cluster Bearish 4/10 Entry $238.88 to $238.19 Now $238.19 +0.29% ▲ +0.29% −3.17% vs SPY
  5. Oct 7, 20265w ago 144 Neutral 3/10 Entry $226.73 to $240.51 Now $238.19 +5.05% ▲ +6.08% +11.37% vs SPY
  6. Oct 1, 20266w ago DEFA14A Neutral 2/10 Entry $218.89 to $229.94 Now $238.19 +8.82% ▲ +5.05% +6.86% vs SPY
  7. Oct 1, 20266w ago DEF 14A Neutral 4/10 Entry $218.89 to $252.83 Now $238.19 +8.82% ▲ +15.51% +17.31% vs SPY
  8. Oct 1, 20266w ago Press Release Neutral 1/10 Entry $218.89 Now $238.19 +8.82% No price data
  9. Sep 10, 20269w ago Insider Cluster Neutral 4/10 Entry $219.58 to $226.73 Now $238.19 +8.48% ▲ +3.26% +1.13% vs SPY
  10. Aug 11, 202613w ago Insider Cluster Neutral 2/10 Entry $224.84 to $219.95 Now $238.19 +5.94% ▼ −2.17% −1.12% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens Wed (11h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026